ATE243529T1 - Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie - Google Patents

Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie

Info

Publication number
ATE243529T1
ATE243529T1 AT96910309T AT96910309T ATE243529T1 AT E243529 T1 ATE243529 T1 AT E243529T1 AT 96910309 T AT96910309 T AT 96910309T AT 96910309 T AT96910309 T AT 96910309T AT E243529 T1 ATE243529 T1 AT E243529T1
Authority
AT
Austria
Prior art keywords
treatment
combination
ace inhibitors
ventricular hypertrophy
aldosterone antagonists
Prior art date
Application number
AT96910309T
Other languages
English (en)
Inventor
Todd E Maclaughlan
Alfonso T Perez
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE243529T1 publication Critical patent/ATE243529T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
AT96910309T 1995-02-10 1996-02-09 Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie ATE243529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38685295A 1995-02-10 1995-02-10
PCT/US1996/001969 WO1996024373A2 (en) 1995-02-10 1996-02-09 Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist

Publications (1)

Publication Number Publication Date
ATE243529T1 true ATE243529T1 (de) 2003-07-15

Family

ID=23527334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910309T ATE243529T1 (de) 1995-02-10 1996-02-09 Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie

Country Status (13)

Country Link
EP (2) EP1136078A3 (de)
JP (1) JPH11507012A (de)
KR (1) KR19980702099A (de)
AT (1) ATE243529T1 (de)
AU (1) AU5354196A (de)
BR (1) BR9604882A (de)
CA (1) CA2212713A1 (de)
DE (1) DE69628821T2 (de)
DK (1) DK0808172T3 (de)
ES (1) ES2205023T3 (de)
NZ (1) NZ305528A (de)
PT (1) PT808172E (de)
WO (1) WO1996024373A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814422A (pt) * 1997-12-23 2000-10-10 Warner Lambert Co Combinações de inibidor de ace - inibidor de mmp
DE69942009D1 (de) * 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
HUP0104249A3 (en) 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU2001255730A1 (en) * 2000-04-26 2001-11-07 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
KR101245877B1 (ko) 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Gdf-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
CN102421433B (zh) * 2009-03-26 2015-09-23 阿贾伊·古普塔 用于治疗肾病的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
AU7854094A (en) * 1993-10-04 1995-05-01 Handforth Investments Ltd. Use of amiodarone for the treatment of heart failure

Also Published As

Publication number Publication date
JPH11507012A (ja) 1999-06-22
EP0808172B1 (de) 2003-06-25
KR19980702099A (ko) 1998-07-15
DE69628821D1 (de) 2003-07-31
ES2205023T3 (es) 2004-05-01
DK0808172T3 (da) 2003-10-20
EP0808172A2 (de) 1997-11-26
AU5354196A (en) 1996-08-27
WO1996024373A2 (en) 1996-08-15
EP1136078A2 (de) 2001-09-26
EP1136078A3 (de) 2002-07-24
CA2212713A1 (en) 1996-08-15
WO1996024373A3 (en) 1996-09-26
BR9604882A (pt) 1998-05-19
NZ305528A (en) 2001-05-25
DE69628821T2 (de) 2004-05-06
PT808172E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69533058D1 (de) Speicherplattenanordnung mit redundanter Speicherung und Verfahren zur inkrementalen Redundanzerzeugung während des Datenschreibens auf die Speicherplattenanordnung
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
EP1059100A3 (de) Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Corticotropin Auslöse Faktor (CRF) Antagonisten enthalten
MY114347A (en) Synergistic therapeutic compositions and methods.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69628821D1 (de) Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie
ATE209047T1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
EA200100951A1 (ru) Комбинированная терапия ингибитором ангиотензинпревращающего фермента и эпоксистероидным антагонистом альдостерона для лечения сердечно-сосудистого заболевания
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE181668T1 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
ATE236653T1 (de) Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE239497T1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
DE60023554D1 (de) Verfahren zum verbessern der weichheit und vermindern des knitterns von gewebe
DE69625254D1 (de) Zusammensetzungen und verfahren zum konservieren von lebenden geweben
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0808172

Country of ref document: EP

REN Ceased due to non-payment of the annual fee